Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
i larger » _ larger (Expand Search), i large (Expand Search), _ large (Expand Search)
c large » _ large (Expand Search), b large (Expand Search), i large (Expand Search)
a large » _ large (Expand Search)
Showing 41 - 60 results of 2,849 for search '(( c large decrease ) OR ((( i larger decrease ) OR ( a large decrease ))))', query time: 0.59s Refine Results
  1. 41
    Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023.

    Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Save to List
    Saved in:
  2. 42
    Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023.

    Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Save to List
    Saved in:
  3. 43
    Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific.

    Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

    Published 2025
    Save to List
    Saved in:
  4. 44
    Data Sheet 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf

    Data Sheet 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  5. 45
    Data Sheet 1_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf

    Data Sheet 1_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  6. 46
    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage.

    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

    Published 2025
    Save to List
    Saved in:
  7. 47
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 48
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 49
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 50
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 51
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 52
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 53
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 54
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 55
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 56
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 57
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 58
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 59
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 60
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: